HOW TRANSPARENT IS NH? FOLLOW OUR SCORECARD

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

739.18 +12.71 (+1.75%)
Delayed Quote Updated: 11:22 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
66 67 Next >
News headline image
Assessing Regeneron Pharmaceuticals: Insights From 7 Financial Analysts ↗
 
Via Benzinga
News headline image
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
News headline image
Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study ↗
Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline. 
Via Benzinga
News headline image
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
News headline image
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
News headline image
These S&P500 stocks are gapping in today's session ↗
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
News headline image
Is Regeneron Pharmaceuticals Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street ↗
Via The Motley Fool
News headline image
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years ↗
Via The Motley Fool
News headline image
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies. 
Via Benzinga
Topics Government World Trade
News headline image
In a market where value is scarce, REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers a refreshing opportunity with its solid fundamentals. ↗
Uncover the potential of REGENERON PHARMACEUTICALS, an undervalued stock. NASDAQ:REGN maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
News headline image
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies ↗
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy. 
Via Stocktwits
Topics ETFs Government
News headline image
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9. 
Via Investor's Business Daily
News headline image
$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors ↗
Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study. 
Via Benzinga
News headline image
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares? ↗
The FDA is due to make an approval decision in mid-September for a key product from the top pharma company. 
Via Investor's Business Daily
News headline image
Why Pharma and Biotech Stocks Got Thrashed on Tuesday ↗
Via The Motley Fool
News headline image
What's going on in today's session: S&P500 movers ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
News headline image
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls ↗
Unity diabetes study showing durable vision gains with full 36-week data expected in Q2 2025. 
Via Benzinga
News headline image
Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty ↗
Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces potential investor obligations. 
Via Benzinga
News headline image
3 Reasons to Sell REGN and 1 Stock to Buy Instead
What a brutal six months it’s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many shareholders. This might have investors contemplating their next move. 
Via StockStory
News headline image
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Price Over Earnings Overview: Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for... 
Via StockStory
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article